The Cassava Sciences saga: Short sellers, ‘gaming’ the FDA, and the damaging ripple effects
By 
Jaclyn Jaeger2022-03-02T19:48:00
The Federal Drug Administration’s decision last month to deny a citizen petition on behalf of short sellers with positions in Cassava Sciences stock highlights the damage the commonly exploited regulatory process can have on a company, regardless of innocence or guilt.
Related articles
-
ArticleDOJ probe into shadowy underworld of short selling ‘long overdue’
A Department of Justice criminal investigation into illegal short selling is just the latest indication these schemes demand greater scrutiny that chief compliance officers and in-house counsel can no longer afford to ignore.
-
News BriefNasdaq: A majority of financial firms plan to use AI in compliance this year
About 36 percent of financial firms are using artificial intelligence in compliance, and most firms intend to ramp up their reliance on AI in compliance in the next 12 months, according to a new survey by Nasdaq.
-
WebcastCPE Webcast: TPRM - Best Practices for Calculating Inherent Risk
Join this webinar with ProcessUnity to hear expert advice and best practices on how to calculate inherent risk and put it to work for your program.
More from Risk Management
-
ArticleHow food and beverage companies adjust to the throes of tariff woes
On-again-off-again tariffs, a down economy, and a long list of global supply chain disruptions are challenging U.S. food and beverage companies to adjust their supply chain operations in a variety of ways.
-
PremiumTop compliance challenges facing the food and beverage industry
New regulations, changing consumer demands, and global supply chain disruptions – from cost-of-goods inflation to tariffs to raw material shortages, and more – are just a few top challenges reshaping the operations of food and beverage industry today. “These challenges are no longer just logistical—they implicate sourcing risk, contract performance, ...
-
PremiumStudy: Compliance managers must set rules in race to adopt AI agents and copilots
More than half of all compliance teams are “actively using” or “piloting” AI applications, according to a Moody’s report. While most are focusing on streamlining routine tasks, some are developing AI agents and asking vital questions about AI decision-making.